A
TRDA icon

AlphaQuest’s Entrada Therapeutics TRDA Stock Holding History

AlphaQuest’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,629
Closed -$161K – 1913
2025
Q4 		$161K Buy
15,629
+9,154
+141% +$77.2K 0.01% 1545
2025
Q3 		$37.6K Sell
6,475
-33,150
-84% -$194K ﹤0.01% 2001
2025
Q2 		$266K Buy
39,625
+27,963
+240% +$225K 0.03% 959
2025
Q1 		$105K Buy
11,662
+7,616
+188% +$94.9K 0.01% 1284
2024
Q4 		$70K Buy
+4,046
New +$73.3K 0.01% 1205

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaQuest's TRDA Position: Q1 2026 in Review

AlphaQuest sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 15,629 shares — an estimated $161K sold.

AlphaQuest first reported a position in TRDA in Q4 2024 and held it in 5 quarters. The position peaked at $266K in Q2 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • AlphaQuest reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 15,629 Entrada Therapeutics shares in Q1 2026, an estimated $161K.
  • AlphaQuest first reported a position in Entrada Therapeutics in Q4 2024 and held it in 5 quarters.
  • AlphaQuest's Entrada Therapeutics position peaked at $266K in Q2 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.